JANX
Janux Therapeutics, Inc.
Biotechnology · Healthcare · United States
17.83
close · 2026-10-29
value
70
cheaper than peers70
quality
71
stronger fundamentals71
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| EV to EBITDA | 0.13× | 91 |
| price to book | 1.17× | 84 |
| price to sales | 66.43× | 21 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 2.3% | 85 |
| return on equity | -11.7% | 77 |
| operating margin | -916.5% | 23 |
3 of 4 measures available
Facts
| market cap | $1B |
| free cash flow | -$54.0M |
| employees | 108 |
| first trade | 2021-06-11 |
| next earnings | not reported |
| fundamentals updated | 2026-07-29 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.83 | -1.28 | -1.32 | -1.52 |
| free cash flow | -$83.3M | -$44.2M | -$52.4M | -$49.4M |
| net income | -$113.6M | -$69.0M | -$58.3M | -$63.1M |
| revenue | $10.0M | $10.6M | $8.1M | $8.6M |